<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tofersen: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tofersen: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tofersen: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="141358" href="/d/html/141358.html" rel="external">see "Tofersen: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F58134916"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Qalsody</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F58111296"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antisense Oligonucleotide</li></ul></div>
<div class="block doa drugH1Div" id="F58119759"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1a1f0b9b-307c-4dfa-ad3e-6402def7e3f4">Amyotrophic lateral sclerosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Amyotrophic lateral sclerosis</b>
<b>: </b></p>
<p style="text-indent:-2em;margin-left:4em;">Loading dose: <b>Intrathecal:</b> 100 mg every 14 days for 3 doses; follow with maintenance dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36129998','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36129998','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance dose: <b>Intrathecal:</b> 100 mg every 28 days, starting 28 days following third loading dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36129998','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36129998','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses:</i></p>
<p style="text-indent:-2em;margin-left:4em;">Second loading dose: Administer missed dose as soon as possible, and administer third loading dose 14 days later.</p>
<p style="text-indent:-2em;margin-left:4em;">Third loading dose or maintenance dose: Administer missed dose as soon as possible, and administer next dose 28 days later.</p></div>
<div class="block dora drugH1Div" id="F58119762"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F58119763"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); not expected to undergo metabolism by hepatic enzymes.</p></div>
<div class="block dot drugH1Div" id="F58119764"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;display:inline">Myelitis and/or radiculitis, symptoms: Evaluate and treat as clinically appropriate; tofersen interruption or discontinuation may be necessary.</p></div>
<div class="block doe drugH1Div" id="F58119760"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F58741642"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Neurologic events</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Serious neurologic events including <b>myelitis, aseptic meningitis, nerve root disorder</b> (radiculitis), <b>increased intracranial pressure, abnormal proteins in cerebrospinal fluid</b> (pleocytosis), and <b>papilledema</b> have been reported with tofersen. In a clinical study, most events resolved without drug discontinuation; however, one participant developed myelitis within 1 week of tofersen initiation which required drug discontinuation and treatment with glucocorticoid and plasma exchange; within 3 months, symptoms and imaging findings had resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36129998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36129998'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; the relationship between pleocytosis and serious neurologic events has not been elucidated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36129998','lexi-content-ref-36645488']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36129998','lexi-content-ref-36645488'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F58119717"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Leukocytosis (cerebrospinal fluid: 14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (17%), pain (42%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (14%), myalgia (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal proteins in cerebrospinal fluid (increased<b>: </b>8%)<span class="lexi-table-link-container"> (<a aria-label="Abnormal Proteins in Cerebrospinal Fluid table link" class="lexi-table-link" data-table-id="lexi-content-abnormal-proteins-in-cerebrospinal-fluid" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-abnormal-proteins-in-cerebrospinal-fluid')">table 1</a>)</span><span class="table-link" style="display:none;">Abnormal Proteins in Cerebrospinal Fluid</span>, neuralgia (6%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Abnormal Proteins in Cerebrospinal Fluid" frame="border" id="lexi-content-abnormal-proteins-in-cerebrospinal-fluid" rules="all">
<caption style="text-align:center;">
<b>Tofersen: Adverse Reaction: Abnormal Proteins in Cerebrospinal Fluid</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Tofersen)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Tofersen)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">72</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">36</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Increased cerebrospinal fluid protein</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle rigidity (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aseptic meningitis, increased intracranial pressure, nerve root disorder (radiculitis)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Myelitis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Papilledema</p></div>
<div class="block coi drugH1Div" id="F58111299"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F58134917"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intrathecal [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Qalsody: 100 mg/15 mL (15 mL)</p></div>
<div class="block geq drugH1Div" id="F58134915"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F58262608"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Qalsody Intrathecal)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg/15 mL (per mL): $1,138.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block accres drugH1Div" id="F58851690"><span class="drugH1">Prescribing and Access Restrictions</span>
<p style="text-indent:0em;display:inline">Availability limited to Optum Frontier Therapies Specialty Distributor (1-833-754-6457) via Optum Frontier Therapies Specialty Pharmacy (1-855-768-9727). Additional access information is available at https://www.qalsodyhcp.com.</p></div>
<div class="block adm drugH1Div" id="F58119765"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Intrathecal:</b> Allow refrigerated vial to reach room temperature prior to administration; do not use external heat sources. Do not shake. Prior to administration, remove ~10 mL cerebrospinal fluid using a lumbar puncture needle. Attach a needle to a syringe and withdraw 15 mL (100 mg) tofersen from vial by inserting the syringe needle through center of the vial overseal. Administer with a lumbar puncture needle as an intrathecal bolus injection over 1 to 3 minutes. Tofersen contains no preservatives. Once drawn into the syringe, administer immediately (within 4 hours of removal from the vial) at room temperature; otherwise, it must be discarded. Do not dilute tofersen; external filters are not required. Discard any unused contents from vial.</p></div>
<div class="block use drugH1Div" id="F58111298"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Amyotrophic lateral sclerosis:</b> Treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. <b>Note:</b> Approved under accelerated approval based on reduction in plasma neurofilament light chain; continued approval may be contingent upon verification of clinical benefit in confirmatory trials.</p></div>
<div class="block cyt drugH1Div" id="F58130712"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F58130709"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F58119748"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events were not observed following SUBQ administration of tofersen in animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F58119749"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if tofersen is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F59003835"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Signs and symptoms of neurological events, including aseptic meningitis, elevated intracranial pressure, papilledema, myelitis, and radiculitis.</p></div>
<div class="block pha drugH1Div" id="F58119753"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Anti-sense oligonucleotide that induces ribonuclease H-mediated degradation of superoxide dismutase 1 (SOD1) mRNA, resulting in SOD1 protein synthesis reduction (Miller 2022; manufacturerâ€™s labeling).</p></div>
<div class="block phk drugH1Div" id="F58119754"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Within CNS tissue.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via exonuclease (3'- and 5')-mediated hydrolysis.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~4 weeks (cerebrospinal fluid).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 2 to 6 hours (plasma).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-36129998">
<a name="36129998"></a>Miller TM, Cudkowicz ME, Genge A, et al; VALOR and OLE Working Group. Trial of antisense oligonucleotide tofersen for <i>SOD1</i> ALS. <i>N Engl J Med</i>. 2022;387(12):1099-1110. doi:10.1056/NEJMoa2204705<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofersen-drug-information/abstract-text/36129998/pubmed" id="36129998" target="_blank">36129998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Qalsody.1">
<a name="Qalsody.1"></a>Qalsody (tofersen) [prescribing information]. Cambridge, MA: Biogen MA Inc; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36645488">
<a name="36645488"></a>Wynford-Thomas R, Robertson NP. Amyotrophic lateral sclerosis: an update on treatments from clinical trials. <i>J Neurol</i>. 2023;270(2):1187-1189. doi:10.1007/s00415-022-11553-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tofersen-drug-information/abstract-text/36645488/pubmed" id="36645488" target="_blank">36645488</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 141342 Version 17.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
